Meeting
2017 ASCO Annual Meeting
Investigating novel resistance mechanisms to third generation EGFR TKI osimertinib in non-small cell lung cancer patients using next generation sequencing.
Authors
Qiuxiang Ou
Geneseeq Technology Inc., Toronto, ON, Canada
Qiuxiang Ou , Xue Wu , Hua Bao , Xiaoling Tong , Xiaonan Wang , Xian Zhang , Zhili Chang , Yu Mao , Yang Shao , Caicun Zhou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2572)
DOI
10.1200/JCO.2017.35.15_suppl.2572
Abstract #
2572
Poster Bd #
64
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study).
First Author: Akito Hata
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2021 ASCO Annual Meeting
Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).
First Author: Pasi A. Janne
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi